XSpray is a drug delivery company that specializes in optimizing the performance of challenging drug substances.

The company is primarily focused on improving targeted oral anticancer agents – in particular protein kinase inhibitors – many  of which suffer from poor bioavailability and pH-dependent absorption.

XSpray’s RightSize™ technology provides complete control over particle production, enabling optimization of solid state properties and making it possible to overcome the inherent drawbacks exhibited by many active pharmaceutical compounds.

The proprietary technology is used both to improve the product profile of currently marketed drugs as well as to speed up and enhance the development of new drugs.